Medicine and Dentistry
Rectum Cancer
100%
Surgery
72%
Cancer Surgery
35%
Colorectal Carcinoma
34%
Surgeon
31%
Surgical Infection
30%
Colectomy
29%
Lower Anterior Resection
24%
Total Mesorectal Excision
23%
Diseases
22%
Recurrent Disease
22%
Colorectal Surgery
22%
Prospective Cohort Study
21%
Anastomosis Leakage
20%
Colon Carcinoma
19%
Surgical Anastomosis
19%
Malignant Neoplasm
19%
Pelvic Exenteration
18%
Neoplasm
18%
Quality of Life
18%
Laparoscopic Surgery
18%
Postoperative Complication
17%
Rectum Resection
17%
Crohn's Disease
17%
Stoma
15%
COVID-19
15%
Metastatic Carcinoma
15%
Chemoradiotherapy
14%
Colon
14%
Randomized Controlled Trial
14%
Cohort Analysis
14%
Odds Ratio
13%
Gastrointestinal Surgery
12%
Neoadjuvant Therapy
11%
Overall Survival
11%
Elective Surgery
11%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Radiation Therapy
10%
Liver Metastasis
10%
Magnetic Resonance Imaging
10%
Surgical Technique
10%
Infection
10%
Randomized Clinical Trial
9%
Surgical Mortality
9%
Coloanal Anastomosis
9%
Antibiotics
9%
Systematic Review
9%
Colostomy
9%
Health Care Cost
8%
Hazard Ratio
8%
Keyphrases
Colorectal Cancer
86%
Colorectal Surgery
33%
Surgeons
30%
Crohn's Disease
30%
Transanal Total Mesorectal Excision (taTME)
25%
Locally Advanced Rectal Cancer
25%
Surgical Site Infection
22%
Colon Cancer
21%
Pelvic Exenteration
19%
COVID-19
18%
Low Anterior Resection Syndrome
17%
Prospective Cohort Study
17%
Tumor
17%
Resection
16%
Locally Advanced
16%
Anastomotic Leak
15%
Colorectal Anastomosis
15%
Colon
15%
Quality of Life
15%
Local Recurrence
14%
Gastrointestinal Surgery
14%
Robotics
14%
Oncological Outcomes
14%
Overall Survival
13%
Elective Surgery
13%
Laparoscopic Surgery
13%
Postoperative Mortality
13%
Microsatellite Instability-high (MSI-H)
12%
Rectal Resection
12%
Neoadjuvant Therapy
12%
Spain
11%
Delphi Method
11%
Anastomosis
11%
Surgical Treatment
11%
Multicenter Cohort Study
11%
Patient Management
10%
Odds Ratio
10%
Major Complications
10%
Risk Factors
10%
Cancer Surgery
10%
Colorectal Cancer Patients
10%
International Cohort
9%
Hazard Ratio
9%
Metastasis
9%
Open Surgery
9%
Oral Antibiotics
9%
Prospective Audit
9%
Minimally Invasive
9%
Mid-low Rectal Cancer
9%
Neoadjuvant Chemoradiotherapy (nCRT)
9%